A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARPi Exposure
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The PamiAP will be a Phase II, single-arm, open label study to explore the efficacy and
safety of Pamiparib treatment in patients with Epithelial Ovarian Cancer（EOC） who have had
exposure to prior a PARPi (inhibitor of poly(ADP-ribose)-polymerase)